Add listing
    0
    Add listing

    Recolony AG Verified listing

    • Swiss Biotech Association
      Member

    Recolony focuses on the development of cancer therapies based on microbial-derived products. These drugs have an enormous influence on our immune system, enhancing an immune reaction against cancer. With this approach, Recolony will develop a new class of drugs for the treatment of cancer.

    Products, services, technology

    RCLBP01: Live Biotherapeutic Product for the treatment of colorectal cancer and other types of solid tumors.
    RCLM01: Microbial-derived metabolite for the treatment of solid tumors.
    RCLB01: Biomarker for early detection of CRC and therapy efficacy

    Location
    Additional address info
    • F Floor
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2022
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in